5770-77-4

Basic information

• Product Name: 1-(4-methoxyphenyl)-3-(morpholin-4-yl)propan-1-one
• Synonyms: 1-(4-Methoxyphenyl)-3-(4-morpholinyl)-1-propanone; 1-(4-Methoxy-phenyl)-3-morpholin-4-yl-propan-1-one; 4'-Methoxy-3-morpholino-propiophenone
• CAS NO: 5770-77-4
• Molecular Formula: C₁₄H₁₉NO₃
• Molecular Weight: 249.3056
• Mol File: 5770-77-4.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 399.3°C at 760 mmHg
• Flash Point: 195.3°C
• Density: 1.102g/cm³
• Vapor Pressure: 1.38E-06mmHg at 25°C
• Refractive Index: 1.524
• CAS DataBase Reference: 1-(4-methoxyphenyl)-3-(morpholin-4-yl)propan-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-methoxyphenyl)-3-(morpholin-4-yl)propan-1-one(5770-77-4)
• EPA Substance Registry System: 1-(4-methoxyphenyl)-3-(morpholin-4-yl)propan-1-one(5770-77-4)

Safety Data

• Hazardous Substances Data: 5770-77-4(Hazardous Substances Data)

Usage

Description

1-(4-methoxyphenyl)-3-(morpholin-4-yl)propan-1-one is a chemical compound with the molecular formula C14H19NO3. It is a ketone derivative that contains a morpholine ring and a methoxyphenyl group. 1-(4-methoxyphenyl)-3-(morpholin-4-yl)propan-1-one is commonly used in the pharmaceutical industry as a research chemical and has been studied for its potential therapeutic effects.

Uses

Used in Pharmaceutical Industry:
1-(4-methoxyphenyl)-3-(morpholin-4-yl)propan-1-one is used as a research chemical for the development of new drug compounds, particularly in the field of neuroscience and psychiatric disorders. Its unique structure with a morpholine ring and a methoxyphenyl group may contribute to its potential therapeutic effects.
Used in Organic Synthesis:
1-(4-methoxyphenyl)-3-(morpholin-4-yl)propan-1-one is also used as a useful building block for the synthesis of other organic compounds. Its precise properties and potential uses in this area are still under investigation, and further research is needed to fully understand its potential applications in organic synthesis.

Upstream product

• 104-92-7 1-bromo-4-methoxy-benzene 
• 405212-49-9 N-methoxy-N-methyl-3-morpholinopropanamide 
• 5765-65-1 4-(benzoyloxy)morpholine 
• 15973-65-6 1-(4-methoxyphenyl)cyclopropan-1-ol 
• 110-91-8 morpholine 
• 2138-33-2 3-(dimethylamino)-1-(4-methoxyphenyl)propan-1-one 
• 35999-20-3 3-chloro-4'-methoxypropiophenone 

Downstream Products

• 71035-25-1 (E)-1-(4-methoxyphenyl)-3-morpholinoprop-2-en-1-one 
• 36907-94-5 3,4-bis-(4-methoxy-phenyl)-1,6-di-morpholin-4-yl-hexane-3,4-diol 
• 5739-24-2 1-cyclohexyl-1-(4-methoxy-phenyl)-3-morpholin-4-yl-propan-1-ol 
• 17492-60-3 (4-methoxyphenyl)(3-phenyl-4,5-dihydroisoxazol-5-yl)methanone 
• 5760-82-7 1-(4-methoxy-phenyl)-3-morpholin-4-yl-1-phenyl-propan-1-ol 
• 6269-84-7 α-<2-Morpholino-aethyl>-α-<4-methoxy-phenyl>-piperonylalkohol 

Relevant articles and documents

Identification of dual Sigma1 receptor modulators/acetylcholinesterase inhibitors with antioxidant and neurotrophic properties, as neuroprotective agents

In this manuscript we report on the design, synthesis and evaluation of dual Sigma 1 Receptor (S1R) modulators/Acetylcholinesterase (AChE) inhibitors endowed with antioxidant and neurotrophic properties, potentially able to counteract neurodegeneration. The compounds based on arylalkylaminoketone scaffold integrate the pharmacophoric elements of RRC-33, a S1R modulator developed by us, donepezil, a well-known AChE inhibitor, and curcumin, a natural antioxidant compound with neuroprotective properties. A small library of compounds was synthesized and preliminary in vitro screening performed. Some compounds showed good S1R binding affinity, selectivity towards S2R and N-Methyl-D-Aspartate (NMDA) receptor, AChE relevant inhibiting activity and are potentially able to bypass the BBB, as predicted by the in silico study. For the hits 10 and 20, the antioxidant profile was assessed in SH-SY5Y human neuroblastoma cell lines by evaluating their protective effect against H2O2 cytotoxicity and reactive oxygen species (ROS) production. Tested compounds resulted effective in decreasing ROS production, thus ameliorating the cellular survival. Moreover, compounds 10 and 20 showed to be effective in promoting the neurite elongation of Dorsal Root Ganglia (DRG), thus demonstrating a promising neurotrophic activity. Of note, the tested compounds did not show any cytotoxic effect at the concentration assayed. Relying on these encouraging results, both compounds will undergo a structure optimization program for the development of therapeutic candidates for neurodegenerative diseases treatment.